As a biotechnology company with a focus on treating rare, infectious, and other diseases, Sarepta Therapeutics Inc (SRPT, Financial) has been at the forefront of developing novel pharmaceutical products to address key unmet medical needs. However, the company's recent stock performance and ownership trends have sparked interest among investors. Let's delve deeper into the dynamics of institutional and insider ownership of Sarepta Therapeutics Inc and what it means for potential investors.
Stock Performance and Market Capitalization
Sarepta Therapeutics Inc experienced a decline of about 5.45% in its stock value over the past week. As of October 02, 2023, the stock fell by 0.8%, contrasting with its three-month return of 5.65%. A closer look reveals fluctuations in its market cap, which dropped to $10.68 billion in the most recent quarter from $12.84 billion in the preceding one.
Institutional Ownership and Key Players
The company's institutional ownership history reveals the levels of trust and confidence that major players have in the company's future. As of August 31, 2023, Sarepta Therapeutics Inc's institutional ownership level is 59.46%, up from 57.13% as of May 31, 2023, but down from 72.45% from a year ago.
Among the top stakeholders, Vanguard Health Care Fund (Trades, Portfolio), Ken Fisher (Trades, Portfolio), and Jefferies Group (Trades, Portfolio) own 2.45%, 0.02%, and 0% of shares outstanding respectively.
Earnings: Past and Future
Over the past three years, Sarepta Therapeutics Inc's Ebitda growth averaged 8.8% per year, which is better than 53.74% of 1258 companies in the Biotechnology industry. However, the estimated earnings growth for Sarepta Therapeutics Inc is 0% per year, lower than the earnings growth of 6.1% during the past three years.
Insider Ownership and Activities
Insider ownership offers insights into the convictions of the company's board directors and C-level employees. Sarepta Therapeutics Inc's insider ownership is approximately 16.51% as of August 31, 2023, compared to insider ownership of 17.58% from a year ago, reflecting the decreased faith of those intimately familiar with the company's operations.
Next Steps
In the ever-evolving realm of stocks, understanding the nuances of ownership and earnings is critical. Sarepta Therapeutics Inc's recent dip is a case study in how major players react to market shifts, and their movements offer crucial insights for potential investors. As always, a holistic view, combining both past performance and future projections, remains key to sound investment decisions.
Screen for stocks with high Insider Cluster Buys using the following page: https://www.gurufocus.com/insider/cluster.
